GenScript ProBio / Genscript
GenScript Life Science Group входит в GenScript Biotech Corporation (основана в 2002 г. в Нью-Джерси). Поставляет исследователям и компаниям базовые компоненты для разработки лекарств и продуктов; сотрудничает с университетами и промышленными компаниями. Около 6165 сотрудников, более 200 000 клиентов в 100+ странах и регионах, включая 20 крупнейших фармкомпаний мира.
Профиль
GenScript Biotech Corporation is a global biotechnology company founded in 2002 in New Jersey, USA, that provides life science research services, biologics development, and industrial synthetic biology tools. It operates through three primary platforms: GenScript Life Science Group (research services and products), ProBio (an end-to-end CRDMO for biologics and cell and gene therapy), and Bestzyme (industrial enzymes).
The company is publicly listed on the Hong Kong Stock Exchange (HKEX: 1548). As of December 31, 2025, it employed 6,165 people and served over 265,000 customers across more than 100 countries. In 2025, the group reported US$959.5 million in revenue. The company maintains a significant 47.18% equity interest in Legend Biotech, which focuses on cell therapies.
GenScript remains highly active in 2026. Recent developments include the implementation of the GenScript Business System to drive operational excellence, the expansion of AI-driven automated manufacturing, and a planned spin-off and separate listing of its ProBio subsidiary on the HKEX Main Board, which received approval from the Listing Committee in August 2026.
Sources#
- Отрасль
- Косметика, Диагностика, Энергетика, Корма, Промышленная химия, Семена и генетика, Текстиль и кожа
- Темы
- Синтез генов, секвенирование и биоинструменты, Платформы синтетической биологии и биопроизводство
- Роль
- Наука / R&D — “…**R&D** - State-of-the-art research center in Philadelphia ( ) **Leadership (website)** - Shiniu Wei — Chief F…”
Биорешения, которые поставляет 0
Пока не указана поставщиком в решениях с доказательствами.
Что предлагают
Продукты: Catalog Peptide; Diabetes & Obesity Peptides; Neuroscience Peptides; Cosmetic Peptide; Cell Penetrating Peptides; AccuPep + QC; Custom Peptide; TurboTIDE; Neoantigen Peptide; Cyclic Peptide
Сертификаты: EcoVadis Bronze rating
- Применение
- life science research · gene synthesis · protein expression · antibody development · Diabetes Research · Neuroscience · Cosmetics · Drug Development · Fundamental Research · Biotechnology advancements · Cell and gene therapy · Gene synthesis
- Сертификаты (сайт)
- EcoVadis Bronze rating
- Клиенты и партнёры
- 20% non-profit organizations · 80% industrial customers · Over 39,000 active customers in 1H
- Производственные площадки
- New Jersey — Improving site utilization rate with 30% YoY growth.; Gene synthesis and protein services · Singapore — 8BD gene to protein services.; Automated gene service · Seattle — Revenue growth over 100%.; mRNA and Gene Fragment services · Piscataway, NJ, USA
- Продукты (сайт)
- Catalog Peptide — Extensive range of off-the-shelf peptides for diverse research applications. · Diabetes & Obesity Peptides · Neuroscience Peptides · Cosmetic Peptide · Cell Penetrating Peptides · AccuPep + QC — Reduces experimental troubleshooting, increases data reliability & ensures reproducible results. · Custom Peptide — Tailored peptide synthesis with various modifications. · TurboTIDE — 5-Day Guarantee for custom peptides. · Neoantigen Peptide — Peptides designed for targeted immuno-oncology applications. · Cyclic Peptide — Synthesis of cyclic peptides with optimal stability and function. · GLP-1 Receptor Agonist — Peptide designed for metabolic diseases. · Cosmetic Peptide — Custom peptides for cosmetic applications.
- Научные центры (R&D)
- State-of-the-art research center in Philadelphia
Прочитано на сайте компании: about · products · production · quality · rnd · leadership · sustainability · topic
Дочерние компании: Probio Technology Limited (ProBio) · Bestzyme Biotech Corporation (Bestzyme) · Legend Biotech Corporation (Significant investment)
Новости и статус 6
- 2026-08 Последний статус: Компания готовит выделение дочерней ProBio и её отдельный листинг на основной площадке биржи; 14 августа 2026 г. это подтвердил листинговый комитет. ↗ ↗ ↗
- 2026-09-16 金斯瑞与礼来TuneLab达成重要合作 紧抓AI赋能战略机遇GenScript (Genscript ProBio) is expanding its AI-driven drug discovery capabilities by partnering with Eli Lilly’s Lilly TuneLab platform to provide wet-lab validation services, bridging AI predictions with experimental data and accelerating candidate …
- 2026-09-23 GenScript's Bestzyme Completes 100-Ton Sweet Protein Line in China - vegconomist - the vegan business magazineGenScript ProBio/GenScript is expanding into high-capacity, automated sweet-protein production through its Bestzyme subsidiary, demonstrating aggressive bioprocess scale-up (100+ tons/year) and venture into integrated fermentation-to-drying operations to …
- 2026-09-04 Genscript shares slump 12pc on proposed spinoff of Probio Technology – Hong Kong United Times丨Dialogue with the WorldGenScript Biotech’s shares fell about 12% after announcing a proposed spin-off and separate listing of its subsidiary ProBio Technology (Probio Technology). ProBio would remain a subsidiary with GenScript holding a controlling stake, and its financials would …
- 2026-09-16 GENSCRIPT BIOTECH | Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO SolutionsGenscript ProBio (GenScript Biotech unit) and KunTuo announce a strategic collaboration to deliver integrated CDMO-CRO solutions for advanced therapies in China, aiming to accelerate investigator-initiated trials and streamline clinical operations.
- 2026-09-18 Genscript Biotech Corporation Enters Agreement with Eli Lilly and Company to Join Lilly TuneLab Collaborative AI-Enabled Drug Discovery Platform | MarketScreener Hong KongGenScript Biotech Corporation (Genscript) has entered an agreement to join Eli Lilly’s TuneLab AI-enabled drug discovery platform, offering preferred-rate wet-lab services to TuneLab members to convert AI predictions into biological data, signaling expanded …
- 2026-09-17 GENSCRIPT BIOTECH | GenScript Biotech hits near 5-year high on Eli Lilly collaborationGenScript Biotech is rallying after announcing a collaboration with Lilly TuneLab (Eli Lilly’s AI-driven drug discovery platform), with GenScript providing wet-lab services to translate AI predictions into validated data, helping accelerate drug candidate …
Связи: владельцы, партнёры, аналоги
Владельцы и инвесторы 4
| материнская | Genscript Biotech Corporation |
| дочерняя | Pherobio Technology Co., Ltd |
| дочерняя | Bestzyme Biotech Corporation |
| дочерняя | Legend Biotech Corporation |
Похожие компании
Tsingke Biotech · Aurisco Pharmaceutical Co.,Ltd · Takara Bio Inc. · ST PHARM · Pepmic Co., Ltd · Bioplus Life Sciences · OBiO Tech · WuXi Biologics
Реквизиты и контакты
Контакты, руководители и юридические данные доступны участникам.
Войти как участник